Phathom Pharmaceuticals (PHAT) EBITDA Margin (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of EBITDA Margin data on file, last reported at 26.55% in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 26.55%, up 24998.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 47.15% (up 30269.0% YoY), and the FY2025 annual result was 91.36%, up 41082.0% from the prior year.
• EBITDA Margin declined to 26.55% in Q1 2026 per PHAT's latest filing, from 10.29% in the prior quarter.
• Over five years, EBITDA Margin peaked at 10.29% in Q4 2025 and troughed at 10245.6% in Q4 2023.
• A 4-year average of 1608.89% and a median of 238.41% in 2024 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2024 and 2025: EBITDA Margin surged 1004530 bps in 2024, then jumped 19001 bps in 2025.
• A 4-year view of EBITDA Margin shows it stood at 10245.6% in 2023, then surged by 98 bps to 200.3% in 2024, then jumped by 95 bps to 10.29% in 2025, then tumbled by 158 bps to 26.55% in 2026.
• Business Quant data shows PHAT's EBITDA Margin at 26.55% in Q1 2026, 10.29% in Q4 2025, and 30.85% in Q3 2025.